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ABSTRACT
Novartis Technical Operations is considering a complete overhaul of their manufacturing processes.
To date, all drugs have been made by using a batch process. In an attempt to lower costs, Novartis is
evaluating moving some drug production to a continuous process. Novartis has instituted lean in
their production plants and it has been very successful, but what is on the table now is a way to
bring lean to the highest level, and a chance to make a seismic shift in manufacturing performance.
The continuous manufacturing initiative between Novartis and MIT exists to pursue that idea.
My task was to evaluate the economic impact and feasibility of spray drying on drug manufacturing.
Spray drying is an advanced manufacturing technique that could allow Novartis to skip multiple
steps in chemical & pharmaceutical operations. It is also a process that can be used continuously. I
investigated the use of spray drying with X, one of the drugs in Novartis' product pipeline.
The major results of this investigation are that drug solubility in the solvent is a critical variable and
that X is stable after spray drying. All experiments in the scientific section were performed with the
drug dissolved in Ethanol, and all experiments resulted in stable versions of X combined with
various additives. The drug solubility directly affects the number of spray dryers necessary for
production within an allocated time span. Using economic assumptions that are detailed later in this
work, there is a breakeven point for most drug volumes at around 3% drug solubility, assuming
additives poses no problems for dissolution. Despite economies of scale considerations and factory
adjustments, this breakeven point is accurate for drug demands from 1 ton/year to 100 tons/year.
Since my experiments were performed at 1.53% drug solubility (too low), I did not prove the
economic viability of spray drying X in particular, but rather laid a framework for future studies.
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GLOSSARY
API: Active Pharmaceutical Ingredient
CHAD: Chemical Research & Development, part of TRD
ChemOps: Chemical Operations, part of TechOps
DS: Drug Substance; End result of Chemical Operations
DP: Drug Product; End result of Pharmaceutical Operations (the pill)
Excipient: Benign agent used to stabilize drug or provide a medium for its bio-distribution
GC: Gas Chromatography
PHAD: Pharmaceutical Research & Development, part of TRD
PharmOps: Pharmaceutical Operations, part of TechOps
Polymorph: One of many different structures of the same material. Generally related to crystal
structure; solids which form chemical composition can exhibit different crystal lattice forms
TechOps: Technical Operations, division in charge of drug manufacturing
TRD: Technical Research & Development, division in charge of development and scale-up
XRD: X-ray Diffraction
INTRODUCTION
1 Problem Context
1.1 Novartis Pharmaceuticals
Novartis was founded in 1996 from the merger of Ciba-Geigy and Sandoz. It is headquartered in
Basel, Switzerland and employs nearly 100,000 people. In 2007, Novartis had $38.07B in sales from
operations divided between pharmaceuticals ($24.03B), Sandoz ($7.17B), consumer health ($5.43B),
and vaccines & diagnostics ($1.45B). The pharmaceutical division, which accounted for 63% of sales
in 2007, focuses on general medicines for arthritis, bone, cardiovascular & metabolism, dermatology,
gastrointestinal, hormone replacement therapies, infectious diseases, neuroscience, respiratory, as
well as special medicines for oncology & hematology, transplantation & immunology, and
opthalmics. Its most recent blockbuster drugs (>$1B in annual sales) were Diovan for hypertension,
Gleevec for leukemia, Zometa for bone cancer, and Sandostatin for neuroendocrine tumors.
Please refer to the following schematic, in order to get a better understanding of Novartis' drug
development process, and to see how the divisions of Drug Discovery, Drug Development, and
Technical Operations operate (note: Phase VI should read Phase IV):
Figure 1: Drug development process
Drug Discovery (DO - PoC)
Like most bio-focused companies, research is a key part of Novartis' pharmaceutical strategy. Most
of the research is conducted at the Novartis Institutes for BioMedical Research (NIBR), which is
headquartered in Cambridge, Massachusetts. In addition to this engine of organic growth, Novartis
supplements its own work through collaborations with biotechnology companies and academic
institutions throughout the world. Finally, Novartis also licenses drugs from other companies and
acquires those with strategic intellectual property. Drug discovery is where compounds are tested for
their possible impact on the human body. The focus of this division is on determining the
effectiveness of new compounds; as a result, drug synthesis can be a long arduous process.
Technical Research & Development (PoC - SDP)
Once the Drug Discovery division has come up with an attractive compound, Technical Research &
Development (TRD) takes over. Another highly technical organization, TRD is conducted mainly in
Basel, Switzerland, and is composed of scientists, pharmacists, and process engineers whose main
objectives are two-fold:
1. Determine the most economical route to producing large quantities of the new compound
2. Formulate an economical dosage form for the compound that results in good bioavailability
These two distinct objectives result in the segmentation of the TRD. Chemical Development
(CHAD) is assigned the first objective and Pharmaceutical Development (PHAD) is assigned the
second. This is the first time where in a drug's life throughout the approval process there is such a
divergence; this dichotomy of Chemical and Pharmaceutical processes continues on to production,
where there are separate Chemical Operations and Pharmaceutical Operations facilities. In order to
achieve the first objective, the compound synthesis is almost always tweaked with different reagents
and solvents in order to make the process suitable for large-scale manufacturing and in order to
reduce costs. There are many options for dosage forms, such as inhalants, intravenous, and trans-
dermal, but my work concerned exclusively oral dosage in the form of tablets. Dosage form is
selected based upon effectiveness, cost, and patient needs.
While this development process progresses, clinical trials are ongoing.
Technical Operations (Phase IV)
Once TRD has vetted the drug from an economic standpoint and clinical trials have shown positive
impact of the drug resulting in approval by various regulatory bodies, the drug is ready for
production. Technical Operations (TechOps) is in charge of manufacturing the active ingredient at
Chemical Operations (ChemOps) plants and manufacturing the drug at Pharmaceutical Operations
(PharmOps) plants. These facilities are placed all around the world, both to minimize logistics costs
and to satisfy country requirements. TechOps produces a wide variety of drugs with vastly different
annual production amounts.
1.2 Drug Manufacturing
Figure 2: Drug manufacturing schematic
Chemical Operations
Chemical Operations is a subset of TechOps that produces the Drug Substance (DS), which is a
modified form of the Active Pharmaceutical Ingredient (API) to make it easier to ship and use in
PharmOps sites. There are multiple sites throughout the world that do this and their main customers
are PharmOps sites. It is only in the ChemOps sites where compounds are actually changed
chemically - solvents are added, reagents are mixed, and process conditions are changed in order to
synthesize the DS. Reaction sections and separation methods are critical to the success of this
endeavor - most process equipment comes in the form of reaction vessels, dryers, extraction
columns, and filters.
The complexity of the processes required to synthesize various DS' within ChemOps varies widely
with the type of drug. Annual production volumes are determined by weighing the complexity of the
synthesis, the value of the final product, and demand. Meeting those volumes involves intermediate
storage and testing between process steps, leading to additional holdup in overall drug production
time.
Pharmaceutical Operations
Pharmaceutical Operations are starkly different from ChemOps. Since the DS is the main input
along with specific additives (referred to as excipients), most of the unit operations are physical in
nature. The output of a PharmOps plant is the Drug Product (DP), which is ready for patient use.
Like ChemOps, a large degree of versatility is required within a PharmOps plant. The ability to
process the API in its solid form is directly related to the API being a "flow-able powder" - that is, a
powder that is able to move easily through different pieces of process equipment. Therefore, several
different types of granulation exist in order to ensure that the powder produced flows optimally.
Having equipment to handle different types of granulation is only one form of versatility needed
within PharmOps; different types of process steps also exist to ensure that the proper dosage of the
API ends up in the dosage form. This need for quality control with respect to dosage size is
significant, since for certain highly active compounds the dose can be on the order of micrograms in
oral pill.
The processing steps that take place in a PharmOps plant include drying, roller compaction, coating,
tabletting, and encapsulation. Some of these process steps, such as encapsulation, tabletting, and
packaging, are able to operate essentially continuously. However, other process steps such as wet
granulation, milling and coating are currently batch. These batch processes increase the costs of drug
production by both increasing the overall throughput time and necessitating that the intermediates
upstream be stored. Elimination of that intermediate storage would result in massive savings, since it
is almost finished drug product that is not being sold.
Another major consideration within PharmOps is the extensive cleaning regime each piece of
equipment must undergo. In order to ensure no cross contamination between API's and to avoid
microbiological contamination, each piece of process equipment needs to be shut down for several
hours in order to be thoroughly cleaned whenever a new drug is to be proceeds. The downtime
required for this cleaning creates several bottlenecks within the drug manufacturing process, which
contributes to the overall cost of production.
Batch Processing
Most of the operations performed in ChemOps and PharmOps are batch and the inherent nature of
a batch process results in unavoidable waste. Walking through a ChemOps facility you can observe
operators carefully measuring reagents, adding them to reaction vessels, and sometimes cleaning
them. There is very little in the realm of process analytical technology to monitor the progress of a
reaction, but it is not as necessary since the duration of the process and variables are prescribed in
the operations manual. PharmOps facilities are much the same way; you can observe operators
measuring out additives, DS, and mixing them manually. Large containers are all around in order to
facilitate the transfer of intermediates from one process unit to another. The batch nature of these
processes allows the use of the same equipment for the production of many different drugs -
changeovers take time, but that flexibility can be helpful with the unpredictability of drug demand
(especially for a new drug). It also makes production scheduling difficult and causes the lead-time for
drugs to be longer than necessary.
Figure 3: Conventional batch processing
Despite the inherent downsides of batch processing outlined above, Novartis has not remained
behind the times in process improvement. Novartis' Suffern, N.Y. plant is the Swiss company's sole
pharmaceutical production facility in the U.S., and it is now a role model for the corporation.
European facilities are basing some of their Lean Manufacturing objectives on the success in
Suffern, and Novartis has described its vision as striving to be the "Toyota of the Pharma Industry."
Back in 2001, the Suffern plant was the least competitive facility in Novartis' PharmOps portfolio.
Four years later, it was beating records in cycle times, back orders, and production costs. Now it is
the model to follow. All of this was a result of the implementation of Lean from a process,
organizational, and supply chain perspective. Rewards and recognition programs encouraged
employee empowerment, Information Technology upgrades made operators more aware of their
status, and SAP increased transparency throughout the organization. In two years, cycle times for
the major product were reduced 50%, back orders were cut from 19 days to 9 days, and the
organization was completely redesigned into a flatter, more process-oriented organization.
Novartis-MIT Continuous Manufacturing Initiative
In 2007, Novartis and the Massachusetts Institute of Technology launched a 10-year partnership,
known as the Novartis-MIT Center for Continuous Manufacturing. The objective of this
partnership is to develop new technologies that can replace conventional batch operations in the
pharmaceutical industry and result in continuous manufacturing from start to finish. In order to
accomplish this objective, Novartis has pledged to invest $65 M in research activities at MIT.
According to Daniel Vasella, Chairmen and CEO of Novartis, "This partnership demonstrates our
commitment to lead not only in discovering innovative treatments for patients but also in improving
manufacturing processes, which are critical to ensuring a high-quality, efficient and reliable supply of
medicines to patients. Our collaboration with MIT, a worldwide leader in developing cutting edge
technologies, holds the promise to achieve a quantum leap in the production of pharmaceuticals, a
field which has received rather little attention in the past."
Figure 4: Continuous processing schematic
Novartis and MIT expect this collaboration to benefit patients and healthcare providers through
increasing supply availability and the quality of medicines. This way, patients can have quicker and
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more reliable access to the medications they need. As an ancillary benefit, this methodology may also
result in reducing environmental impact of manufacturing activities.
In addition to these rewards for patients, there are other expected benefits:
1. Accelerating the introduction of new drugs by designing production processes earlier
2. Using smaller production facilities with lower building and capital costs
3. Minimizing waste, energy consumption, and raw material use
4. Monitoring quality assurance on a continuous basis rather than post-production testing
5. Enhancing process reliability and flexibility to respond to market demand
1.3 Project Background
My project is an attempt to demonstrate the feasibility and economic benefit of implementing spray
drying, as one milestone on the way to operating a completely continuous process. As a basis for
comparison, one drug (X) was chosen out of Novartis' pipeline; I analyzed the feasibility of spray
drying with that X, as well as the economic impact of using spray drying with that X's expected
conventional manufacturing process. In order to fully cover the context required to understand how
my project fits into the Continuous Manufacturing Initiative, I will discuss what parts of TechOps
we are dealing with and what processes spray drying can replace. Additionally, I will provide some
background on spray drying itself.
As discussed earlier, in ChemOps an intermediate product is the API and the final product is the
DS, whereas for PharmOps the final product is the DP, which is consumed by the patient. Spray
drying is an exceptional technique but it is not traditionally used as a reaction step. As a result, we
need to have an active drug compound, the API. However, it is not necessary for this API to be
fully segregated from other compounds, and so we can implement spray drying before the
conventional production of the DS. This logic brings us to the conclusion that spray drying can be
implemented somewhere between the tail end of ChemOps (also called the end game) and the
beginning of PharmOps.
Below you can see a flowchart of the part of the conventional production process (specific to the
drug studied) relevant to spray drying:
Drug
Solution
(contains API)
ChemOps
Milling
DS
PharmOps
Roller Compaction
Excipient Excipient
DP
Figure 5: Conventional production process
Ideally, we could use the drug solution (containing API) along with excipients as feed for the spray
dryer, produce a powder, and compress the powder directly. This would entail skipping
crystallization, filtering, drying, milling, and roller compaction. That sort of operation would be the
Holy Grail for spray drying implementation. Unfortunately, things are not so easy.
For X, it turns out that the crystallization step is necessary for the removal of a mutagenic
byproduct. Since crystallization is necessary, filtering and drying are also necessary (those steps serve
to eliminate that mutagenic compound). Milling only serves one objective in this process flow: make
the DS very small. This is a requirement so that when excipient is added in the next step, roller
compaction, the mixture of DS and excipient is relatively homogeneous.
Spray drying can replace milling and roller compaction in the conventional production process for
X. By mixing the excipient and the un-milled API in a solvent that dissolves the API, we can achieve
a homogeneous mixture. Here is the proposed process flow:
____
Solvent,
Excipients
Drug
Solution
(contains API)
ChemOps
PharmOps
i i 1-:i r: -
" "'
I:*
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Excipient
DP
Figure 6: Proposed production process
Spray Drying Process & Equipment
Spray drying is a commonly used method of drying a liquid feed with a hot gas. Usually the gas is air,
but sensitive materials like pharmaceuticals and solvent like ethanol require nitrogen. The liquid feed
varies depending on the material being dried and may be a solution, colloid or suspension. This
process of drying is very rapid and effective, and by skipping multiple steps it can result in profit
maximization and process simplification.
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Figure 7: Spray dryer schematic
A spray dryer is a device used in spray drying. It takes a liquid stream and separates the solute or
suspension as a solid and the solvent into a vapor, so it can be thought of as a separations device.
The solid is usually collected in a drum or a cyclone. The liquid feed is sprayed through a nozzle into
a hot vapor stream and vaporized. Solids form as moisture quickly leaves the droplets. A nozzle is
usually used to make the droplets small for a higher surface area to volume ratio.
In addition to its usefulness as a separations technique, spray drying can offer a lot of value as an
encapsulation technique. With a load (in our case, the drug) and a carrier (in our case, an excipient
that does not dissolve in the solvent) in a solvent we can produce homogeneous slurry. Once this
slurry is fed into a spray drier at the right temperature, the atomized slurry forms micelles. The small
size of these drops results in a large surface area, which dries quickly. As the solvent dries, the carrier
(excipient) forms a hardened shell around the load (drug). This application of spray drying
encapsulation has often been used to prepare "dehydrated" powders of substances, like instant drink
mixes and skim milk. In my project, we took advantage of the fact that the slurry was originally
homogeneous, and postulated that we should be able to skip milling and roller compaction, which
are essentially methods of making the DS very tiny and combining it with excipients, to finally result
in homogenous mixture.
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2 Scientific Investigation
The objective of my scientific work was to determine the characteristics of drug X when combined
with different excipients after spray drying. The ideal outcome of this exercise was evidence that
drug X was stable after spray drying under specified process conditions, along with some analysis of
the various structures that resulted.
Spray drying experiments were performed with drug X and four excipients at three different drug
loadings (20%, 50%, 80%). Temperatures were determined by the desire to have a dry sample and
reduce energy requirements; they were held constant throughout the experiments. Ethanol was
chosen as the solvent because it is used often for spray drying and because it can be used to dissolve
X.
After four weeks of stress testing at 400 C and 75% Humidity, X is pronounced stable when
combined with Avicell (Microcrystalline Cellulose), PVP, Lactose, and Aerosil.
X forms a stable polymorph (Acetate, mod. D) with Avicell at 80% drug loading and 50% drug
loading, and a stable amorphous form at 20% drug loading. X forms a stable solid dispersion with
PVP at all drug loadings, a stable amorphous structure on crystalline Lactose at all drug loadings,
and a stable amorphous mixture with Aerosil at all drug loadings.
2.1 Process
Initial process for setting boundary conditions
Before starting experiments with X and excipients, several baseline measurements needed to be
taken and certain process variables set. Excipients were chosen both because they were compatible
with drug X and also because we wanted to characterize drug X interaction with both carriers and
stabilizers. Carriers do not interact with drug X and do not dissolve in the solvent, while stabilizers
have the potential to do both.
1. X-ray diffraction spectra of excipients, drug X, spray dried excipients, and spray dried drug X
were obtained for future comparison. Optical microscopy was also performed on the same samples.
2. Ethanol was chosen as the solvent since drug X is weakly soluble in it and Ethanol is a known
solvent used for spray drying. Furthermore, drug X has documented interactions with other possible
candidate solvents, so this limited our choice dramatically.
3. Temperatures for spray drying operation were set based on the desire for low moisture product
and economical operation. 145' C Inlet, -85o C Outlet.
Spray dryer operation
1. Turn on nitrogen flow for atomization and respiration
2. Set nozzle temperature
3. Introduce pure ethanol as preliminary feed
4. Once temperatures are equilibrated, introduce slurry containing ethanol as solvent, drug X,
and/or excipient
5. Adjust slurry pump rate or nitrogen rate if necessary to maintain the same outlet temperature.
Experimental Process
1. Solutions were prepared of Solvent (ALANP Ethanol), Excipient, and drug X. Homogeneous
solutions were achieved through ultrasonification and shear-mixing.
2. Spray drying procedure followed using prepared solutions and given temperatures (1450 C inlet,
-85o C outlet)
3. Initial analysis of powder product performed using X-ray diffraction (XRD), Gas chromatography
(GC), and Optical Microscopy (OM)
4. Powder product placed in dessicator for two weeks at 75% humidity and 40 C
5. Analysis of "stressed" product using same methods (XRD, GC, OM)
6. Powder product placed in dessicator for two more weeks (four weeks total)
7. Analysis of "stressed" product using same methods (XRD, GC, OM)
8. Differential Scaling Calorimetry (DSC) performed on samples for further characterization
Experimental Data
Filter Inlet outlet
label Dru X Exc n Etanl P OC C recovered ld
Avicell 20% 5 0 1i 86 3
Avicel 50% 5 5 400 ml -77 145 86 5.3 53%:
A anIol Anl/. in A n rfnn m| 1 A.Rr% RR A 1 n A -101i
Figure 8: Mixtures used in the analysis
2.2 Laboratory Analysis
Analysis was done with X-Ray Diffraction (XRD), Gas Chromatography (GC), Optical Microscopy,
and Differential Scaling Calorimetry (DSC). However, XRD was discovered to be the most valuable
method in my work. The reason for this is that the crystal structure (or lack of one) gives insight on
the form that drug X takes after spray drying in combination with excipients, whereas the other
methods only give secondary information (like melting points, moisture content, etc.) on the drug.
The structure X takes after spray drying has consequences for the bio-distribution and stability for
use in an oral form. It can also impact the drug loading possible for that drug, although only
empirical analysis can be done for that factor. Originally, we expected that any amorphous structures
would quickly re-crystallize, thus implying that such a structure would be unstable. This was why we
did stress testing followed by more analysis. It is currently unknown just how much an amorphous
structure would change bio-distribution, since almost all drug products that Novartis sells in the oral
dosage form are crystalline in nature.
We found the GC data to be unhelpful since the moisture could be tuned in a pilot/production scale
setup and preliminary economic work showed that the energy required to vaporize ethanol was an
extremely small portion of the costs of running a spray drying (<1%0/). DSC was worthwhile for full
characterization of the substance, but not completely necessary for my simple analysis. If the final
result of my economic model showed an economic benefit for spray drying drug X, the DSC data
would be useful for work downstream in the new process development product, like pressing the
powder into a pill. Optical Microscopy photos are included in this analysis in order to show the
color and particle size of the powders produced and to bring the analysis from the abstract realm in
to the physical realm. Particle size can also be manipulated by using different operating conditions
on different scale equipment, but I felt it necessary to show that powders were actually produced
and analyzed.
Drug X alone
To begin with, we have found that upon spray drying drug X becomes amorphous. Here is a graph
of micronized crystalline X, with spray dried X for comparison:
2Tht.
Figure 9: Drug X Micronized, Drug X Spray Dried
Drug X and Avicell (Microcrystalline Cellulose)
Next, we see that X is stabilized into a different, stable polymorph (acetate mod. D) at 80 % and 50%
drug loading (Avicell 20% and Avicell 50%) combined with Avicell. The 20% drug loading (Avicell
80%) does not exhibit this polymorph and is instead amorphous. First, we have a graph of the
different drug loadings:
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Figure 10: Drug X and Avicell, different loadings
Second, the 50% drug loading and micronized crystalline X, to show that we have a polymorph,
along with pure spray dried avicell to show that it is amorphous upon spray drying:
ZThhta ()
Figure 11: Determination of Drug X polymorph in Avicell
Third, we show how the actual polymorph was determined; the XRD for 50% drug loading is
combined with appendix 5 from the drug X Salt program report (different polymorphs), and the
closest match is Acetate mod. D (the pure micronized drug X is in form Acetate mod. B):
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Figure 12: Documented polymorphism of Drug X
Optical Microscopy photos of 50% and 80% loading:
In order to demonstrate stability we show the 50% loading at each stage in the stress testing (initial,
two weeks, and four weeks). All drug loadings were stable:
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Figure 13: Drug X and Avicell Stability
Drug X and PVP k-30 (Poly vinylp ryy olidone)
For our second excipient, we see evidence of a solid dispersion. First, this is a graph of the different
drug loadings:
Figure 14: Drug X and PVP Loadings
Next, we have the spectra of spray dried pure X and spray dried pure PVP along with 50% loading
to show the constructive/destructive interference:
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Figure 15: Drug X and PVP evidence of solid dispersion
Here is optical microscopy of the 50% and 80% loading samples, showing the amorphisity (lack of
structure) at various magnifications:
Finally we demonstrate stability by showing the 50% loading at each stage in the stress testing. All
drug loadings were stable:
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Figure 16: Drug X and PVP Stability
Drug X and Spray Dried Lactose
For our third excipient, we see evidence of the excipient remaining in crystalline form while the drug
X deposits an amorphous phase on top of it. First, this is a graph of the different drug loadings:
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Figure 17: Drug X and Lactose Loadings
Next, we have the spectra of pure spray dried Lactose and 50% loading, to show that the peaks are
at the same points, indicating that Lactose remains in crystalline form:
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Figure 18: Drug X and Lactose analysis
Here is optical microscopy of the 50% loading, showing a crystalline base with amorphous blobs on
top:
Finally we demonstrate stability by showing the 50% loading at each stage in the stress testing:
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Figure 19: Drug X and Lactose Stability
Drug X and Aerosil 200
For our fourth and final excipient, we see an amorphous phase. First, this is a graph of the different
drug loadings:
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Figure 20: Drug X and Aerosil Loadings
Next is a graph of pure spray-dried X, pure Aerosil, and 50% aerosil:
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Figure 21: Drug X and Aerosil analysis
This is the 50% loading at different magnifications:
Finally we demonstrate stability by showing the 50% loading at each stage in the stress testing:
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2.3 Conclusion of Scientific Investigation
Spray drying experiments were performed with four excipients (Avicell, PVP, Lactose, Aerosil) at
three different drug loadings (20%, 50%, 80%). Temperatures were determined by the desire to have
a dry sample and reduce energy requirements; they were held constant throughout the experiments
at 145' C inlet and -85o outlet. Ethanol was chosen as the solvent because it is used often for spray
drying and because it can be used to dissolve drug X.
After four weeks of stress testing at 40' C and 75% Humidity, drug X is stable with Avicell, PVP,
Lactose, and Aerosil.
Drug X forms a stable polymorph (Acetate, mod. D) with Avicell at 80% drug loading and
50% drug loading, and a stable amorphous form at 20% drug loading. Drug X forms a stable solid
dispersion with PVP at all drug loadings, a stable amorphous structure on crystalline Lactose at all
drug loadings, and a stable amorphous mixture with Aerosil at all drug loadings. Differential Scaling
Calorimetry data is in the appendix for reference.
3 Economic Investigation
My work was done by comparing spray drying to currently existing and possibly replaceable
technologies used in the production of drug X: milling and roller compaction. Below is a picture
representing the shift that we envision:
Currently existing Proposed operation
Drug Solvent,Drug 
_oluton E.l.tus ,
Solution on
(contains API) (containsAPI)
ch.op. cbmop. . .
- -":rDS
Excipient Excipient
DIP
Exciplent
DP
The most significant result of this investigation is that drug X solubility in the solvent is a critical
variable. All experiments in the scientific section were performed with the drug X dissolved in
Ethanol. The solvent mass directly affects the number of spray dryers necessary for production
within an allocated time span. It does this in two ways: spray dryers are more effective with a lower
solvent content and less total throughput is needed for a lower solvent content. Using my
assumptions that are detailed later in this work, there is a breakeven point for most drug volumes at
around 3% drug X solubility, assuming the excipient poses no problems for dissolution (most likely
a carrier that does not need to dissolve into the solution). Despite economies of scale considerations
and factory adjustments, like allowing larger spray dryers and accounting for increased operating
costs of high mix factories, this breakeven point is accurate for drug demands from 1 ton/year to
100 tons/year. Furthermore, sensitivity analysis has shown that the second most important factor
for the economic feasibility is labor costs, and that none of those variables dramatically affected the
solubility break-even point. Since my experiments were done at 326 gram of solvent per 5 grams of
X (1.53% solubility), I did not prove the economic viability of spray drying drug X in particular. By
varying solubility and keeping all other variables at Novartis' averages and given values, I generated
both of these graphs to show the impact of solubility on drug production savings:
nrmop
Figure 23: Higher solubility => higher savings
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Figure 24: Higher solubility => lower production cost
3.1 Data and Methods
Data used for the model that generated these results was obtained from various sources. Capital
costs for milling and roller compaction were obtained from ChemOps and PharmOps production
personnel. Quotes from NIRO, a widely used spray drying equipment maker, were used for spray
drying capital costs - they currently sell seven designs, all of which were incorporated in the model.
The two main components of operating expenses, labor and equipment, were set by variables in the
API Solubility vs money saved (Mio CHF)
3
2
® 1 -.- 1 tonyear
- 10 tons/year
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model. Equipment expenses were obtained by looking at SAP data for currently existing production,
and labor estimates were obtained from ChemOps personnel. Plant uptime was calculated as an
average over Novartis' portfolio, and acts as a scalar for the economic benefit/loss of spray drying.
Equipment uptime was taken directly from SAP results, so it based on historical data. Other costs
(PharmOps other costs and ChemOps other costs) are included as a percentage of the total
operating expense that can be changed in the model, but are currently at the Novartis accepted rates
for drug X. They include charges for environmental handling and product testing. Overheads
(General Factory Overhead and Process Overhead) are included on a percentage basis on the
recommendation for both ChemOps and PharmOps finance personnel. Production Area Overhead
accounts for costs that have a general character and cannot be allocated directly to products. This
includes indirect labor, indirect space (corridors, break rooms, where manufacturing is not
happening), and training of process personnel. General Factory Overhead refers to expenses
incurred within a plant that are related to production, but cannot be attributed to individual
production areas. This includes plant & production management, safety, health & environment,
production support, engineering, and IT. The higher cost penalties of high mix facilities (instead of
low mix) are added in as a factory adjustment based on historical data. Finally, discussions with
ChemOps finance set the discount rate at 10%.
Novartis' Total Production Cost (TPC) method was used to calculate yearly costs. This method
combines capital costs and expenses into one single number that is the same every year for the life
of the project (15 years). Essentially, the TPC is what you get when you take a net present value and
turn it into an annuity for the lifetime of the project. This allows for easy comparison among
production methods with varying capital costs, and for simple communication of the data.
3.2 Equipment-based, Direct, and Full Costing
The equipment for the X campaign is assumed to be usedfor other campaigns throughout the year
This is by far our most important assumption, and perhaps illustrates why the pharmaceutical
industry is slow to implement new processes. In order to put Spray Drying and conventional
processing on a level playing field, in order to compare apples to apples, it is imperative to use
equipment-based costing. What this means is that capital costs are only assigned for the time the
equipment is in use (whether processing material, cleaning, or in repair related to drug X). The rest
of the time, another drug is assumed to be using the same equipment.
Unfortunately, there are problems with this assumption. If you are only using spray drying with one
specific drug, then it is unlikely that spray dryer will be used the entire year. As such, all capital cost
should be assigned to that drug (full costing). But then, as more drugs are added in spray drying the
cost becomes less and less per drug.
What does this imply for someone actually planning to use spray drying? First, that the outcome of
this model is appropriate in sign (positive or negative) but not in magnitude of financial benefit if
the sprayer is to go in a Greenfield site and only one drug will be spray-dried (due to capacity
constraints in other facilities). Second, the outcome of the model is correct if the spray dryer is used
during all plant uptime in the Greenfield site. Third, the model is not appropriate for Brownfield
sites. If there is excess capacity in existing mills and roller compaction machines, it is quite likely that
they are the best choice to use. The reason is that they are being underutilized and thus any financial
analysis should view them as a sunk cost, and only direct costs should be considered (essentially,
everything but the capital cost of the equipment).
A simple question is, if this model is only appropriate if the spray dryer is up and running during all
plant uptime, why even make it? Simply put, that is the model of continuous manufacturing. The
idea of continuous manufacturing is to make Greenfield sites sized for the correct drug demand and
to produce that drug alone. Flexibility can be added to accommodate more drugs in the same line,
but the idea remains the same - to use the same sort of process equipment, all the time, with very
few changes. Since my project is part of the continuous manufacturing initiative, I chose to present
my model in this manner.
3.3 Model
Model Logic
In order to obtain these results, a model was formulated. The model was based on Total Production
Cost and thus incorporated capital costs and operating costs. As with all models, many assumptions
were taken and they are listed here:
* High mix factories are intrinsically more expensive to run than low mix factories
* Discount rates, overhead rates, labor rates, other financial variables
* Yields are assumed to be 100%
* Estimates on time needed to mill & roller compact
By far the most important and influential assumption is the last one. Run time for each process was
obtained by looking at the average throughput of the average mill and average roller compaction
machine in actual drug production. However, it is quite possible that the runtime would change if
you could use a much larger mill or roller compaction machine.
Why are these numbers so important? They determine the total capital costs for mills, roller
compaction machines and spray dryers, as well as the time those devices are used. That means that
these numbers essentially carry out equipment-based costing. The total capital cost is derived from
looking at the time on stream and calculating the number of machines required to match throughput
for a given drug demand. Spray drying run time is assumed to be the maximum of roller compaction
or mill run time.
It is critical that good data is used for the time needed to mill & roller compact because those values
dramatically impact the case for spray drying.
The yield assumption may seem high, but the average yields from roller compaction and milling
approach that number, as do the yields for spray drying. Furthermore, any change in overall yield for
both technologies would wash out in the calculations.
Spray drying versus conventional processing
There are several considerations when looking at implementing spray drying:
* Less labor required: two workers required for a spray dryer whereas five workers required
for milling and roller compaction combined
* More energy required: this was determined to be negligible by comparing energy cost to boil
and condense solvent to the operating cost of the conventional process
* Less downtime: mills are frequently down for maintenance and cleaning, roller compactor's
not as often, and we expect spray dryers to be down even less
* What is the impact on other costs like ecology and quality assurance? We assumed there was
no impact, but this may not be the correct assumption
Milling and Roller Compaction machine selection
Selection of machine type and number of machines was based on the throughput required by
operating time (variables in the model for both milling and roller compaction) and drug demand (1
ton/year, 10 tons/year, 50 tons/year, and 100 tons/year default values in the model).
Please see below for a snapshot of those calculations:
required throughput milllnglmlcronization roller compaction
1 ton/year 42 kg API/lhour 42 kg API/hour
10 tons/year 60 kg API/hour 69 kg API/hour
50 tons/year 174 kg API/hour 208 kg API/hour
100 tons/year 208 kg API/hour 321 kg API/hour
# machines
1 ton/year 66
10 tons/year 9 "
50 tons/year
100 tons/year 33 ' 5
max throughput/machine 6 kg APi/hour 69 kg API/hour
capital cost/machine CHF i,200,000.00 CHF 2,000,000.00
Figure 25: Calculations for machines required
Spray drying machine selection
Selection of machine type and number of machines was based on the throughput required by
operating time (maximum of the inputted values for milling and roller compaction) and drug
demand (1 ton/year, 10 tons/year, 50 tons/year, and 100 tons/year default values in the model). In
addition, the seven models of NIRO were incorporated into the model so that the user can pick and
choose which spray dryers to use. The number and types of spray dryers is heavily dependent on the
amount of solvent used. Although spray dryers have a rated throughput, there is also a maximum
evaporation rate set by the solids content in the slurry. Higher solids content results in a higher
evaporation rate.
Model Mathematics
In order to demonstrate the interaction of variables, let us look at how the TPC is calculated. Once
all the terms have been identified, all that remains is discounting at the proper rate, developing the
total production cost, and annualizing that cost to present the Novartis TPC.
Here is a section from the discounted cash flow spreadsheet, showing the various variables (and only
years 0, 1, 2, and 3):
CONVENTIONAL
Milling
Milling operating costs
Labor
Maintenance
Depreciation
chemops other costs
Roller compaction
Compactor operating costs
Labor
Maintenance
Depreciation
pharmops other costs
Total Labor & Equipment
Factory adjustment
PAO
GFO
Capital cost
PV Operating cost
total production cost
annualized total production costs
UNCONVENTIONAL
Spray drying
Spray dryer operating costs
Labor
Maintenance
Depreciation
other costs
Total Labor & Equipment
Factory adjustment
PAO
GFO
Capital cost
Operating cost
total production cost
annualized total production costs
Tons: 1 0 1 2 3
30,469.74
693,919.84
46,261.32
53,333.33
280,052.38
18,670.16
47,619.05
529.10
S,763.67
8,807.97
2,890.59
40.15
267.65
479.76
53,110.20
15,933.06
7,966.531
928.77
79,296.63'
9,600.00
355.56
3,555.56
9,287.73
13,511.11
4,053.33
2,026.67
928.77
27,097.83
40.15
267.65
9,287.73
53,110.20
7,966.53
928.77
47,619.05
529.10
1,763.67
2,890.59
40.15I
267.65
9,287.73
53,110.20,
15,933.06
7,966.53
928.77
.. .. .. .. ..  . .... . .. .
72,087.84 65,534A.40
9,600.00 9,600.00
355.56 355.56
3,555.56 3,555.56
9,287.73 9,287.73
13,511.11 13,511.11
4,053.33 4,053.33
2,026.67 2,026.67
928.77 928.77
24,634.39 22,394.90
Figure 26: Discount Cash Flow spreadsheet
Capital Costs
Capital costs are separate from the expenses incurred every year. Capital costs are assigned using
equipment based costing, so:
CapitalCosts - TootalcpitalConm x
MaxUflhitatton
Where DaysRunning is the days the equipment needs to run to produce the required drug demand,
MaxUtilization is the number of days per year the facility operates, and TotalCapitalCost is the total
value of all equipment purchased.
TotalCapitalCost for roller compaction & milling is determined by looking at the required drug
demand, the throughput per machine, and the cost of each machine. Drug demand was varied from
1 ton/year to 100 ton/year in the model. There are provisions in the model to accommodate
different sized spray dryers with different costs, but the general formula is the same:
TotalCapitalCost - x MachineCost
aysRunning x MachineThroughpur
The first term is equivalent to the number of machines used (MachinesUsed).
Direct Expenses
Direct expenses are those incurred by operating the machines. This includes labor, maintenance, and
depreciation. Labor costs are calculated in this manner:
LaborCost - x LaborRate x 24 x Operators
Machi*eThroughput
Since the first term is just MachinesUsed x DaysRunning, we see that the LaborCost equation is self-
explanatory. The LaborRate is given in CHF/hour, 24 hours in a day, and Operators is the variable
for the number of personnel to operate the equipment. This can be different for milling, roller
compaction, and spray drying.
Depreciation is calculated as simply the equipment-based cost (CapitalCost) divided by the number
of years in operation (assumed to be 15).
Maintenance is the maintenance frequency times depreciation, since it is lost time on the machine.
Indirect Expenses
Then there are the indirect expenses like the Factory Adjustment, PAO, ChemOps other costs,
PharmOps other costs, and GFO.
The factory adjustment is based exclusively on direct expenses. It accounts for increased costs of
operating equipment at lower volumes (to account for changeovers):
FacroryAdjustmnr - %Adjust x (Labor + Mainteance+ Depreciaon)
PAO is calculated in the exact same way, except it accounts for indirect labor and other costs
discussed earlier, and so can remain the same no matter what volumes we are dealing with.
PharmOps and ChemOps other costs are calculated in this manner, and are based upon only direct
expenses:
Labor + Maintenance + Depreciation
%OtherCosts
Why such an odd formula? Because the OtherCosts are defined as a percentage of the total
expenses; if we rearrange the equation we get:
OtherCosts - %Othercosrs x (Labor + Maintenance+ Depreciartion + OtherCosts)
Finally, GFO is calculated as a percentage of all the OtherCosts, for the reasons discussed earlier.
Model Operation
Coming up with the rationale and logic behind a model is one thing, whereas operating is a different
model entirely. This model was built to have quite a few variables, because many things are uncertain
in this analysis. On the "Total Production Cost sheet", the most important variables are the time on
stream for milling and roller compaction.
__ _ ____ 
_ _ 
_
Solvent mass urug Loau
Project lifetime (n) ... .. PAO .15%
max utilization I300 day GFO 10%
Discount rate 10% chemops other cost 15%
Labor rate .100 C.H..F/hr .harmops other cost 15%
milling/micronization roller compaction spray drying
workers required per shift 3 2 2
maintenance f2quenc 30% 15% 10%
days running
I ton/year 1 1.
10 tonslyear 7 6 7
50 tons/year 12 101
100 tons/year 20 13
machines (labor)
10 tons/year
50 tons/yea
100 tons/year
Figure 27: Important production variables
The other variables, also highlighted in yellow, are rarely changed, but if new data becomes available
about labor requirements, maintenance frequency, or other costs then changing the values will make
this model more accurate. It is important to know that if the days running numbers are changed, you
need to recalculate the workbook by pressing F9 in windows or "apple" and "=" at the same time
on a Macintosh.
Once the "Total Production" sheet has been manipulated to reflect anticipated (or currently
operating) values then it is necessary to switch to the "Spray Drying EOS" sheet. This is where you
set the solubility of X in the solvent (relates directly to the mass of solvent required to dissolve X),
drug loading, and select the number and types of spray dryers for the model.
Solubility 5% Solvent
Drug load ----- 37% API load
Excipient load
kg solvent / kg API
% solids
Figure 28: Important variables set by chemical properties
The method for selecting spray dryers is as follows:
1. Set all yellow cells to zero
2. Look at throughput required (in red) and drug X kg/hour throughput (in light blue) of the
different spray dryers
.. . . . I
3. Add spray dryers by putting the number chosen in the yellow cell that corresponded with the
spray dryer you want and the drug demand you are trying to accommodate
4. The cells for match-calculated section will turn from violet to green once there are enough
spray dryers to match the necessary throughput
PSD0 PSD2 PSD3 PSD4 P55 PS04 PSD 7fthrouhput W(kgh) 34 47 so 120 180 370
Sof each spay dWr required I we on*y used that type in orde to achieve API kgl requiremeint purety a U to make the eseechn easier
PSD 41 PSD 2 PSDI 3 PSO 4 P5D 5 P304 PSD 7
MATCH IN RED al t ated kp AP matc -calw %1433 ct6 6 4n wh * i is good!10 62 1 7762.I1 i vf hen 4 6drq
coselet besfor the onventional process (milling and rollkger compaction), proposed process (spray drying),usedobjeeove Is to exceed the red ambers at the lowet cost
Figure 29: Spray dryer selection sheet
Once the values on the "Total Production Cost" sheet and the "Spray Drying EOS" sheet have
been chosen, switch back to the "Total Production Cost" sheet and you can see the total production
cost for the conventional process (milling and roller compaction), proposed process (spray drying),
and the difference between the two (delta).
Proposed
Total Production Cost Current Process Process Delta
I tonlyearH C 40
10 tonslyear ... 4.. . " .. .......... 4.5. CMF ...,5...50 tonlyear4 CH
Figure 30: Total Production Costs
Model Applicability and Suggestions
In order for this model to work, it must be used with a drug that undergoes both milling and roller
compaction. These are the operations replaced by spray drying in our analysis. However, the type of
solvent does not matter and the drug loading can be varied.
A way to expand the scope of this model is to allow other types of mixing techniques (other than
roller compaction). This would mean getting the capital costs of all sorts of mixers and granulators
and allowing the user to add them until reaching a required throughput, in a similar manner to the
"Spray drying EOS" sheet. Adding this sort of capability, along with the ability to select
more/different mills, would enable extension of this model to almost any sort of drug.
The benefits of different (cheaper) drying techniques upstream of the spray dryer were considered,
but the data was not gathered in time for rigorous analysis. Liquid/liquid extraction was also
considered as an upstream operation, but once again there was not enough time for a rigorous
analysis.
3.4 Sensitivity Analysis
In addition to the rigorous analysis of the impact of solubility on spray drying feasibility, several
other variables were considered. First, the run length was multiplied for different campaigns; this
resulted in very little difference for economic performance. This was done by doubling the run
length for milling and roller compaction, halving it, and keeping it the same. I did not attempt to try
disparate run lengths for milling and roller compaction because there is a low probability of that type
of operation and it would never happen in a Greenfield facility (milling for 1 day and roller
compaction for 5 days, or one of a million other combinations). Next, labor costs were varied; that
had a profound impact on the economic viability of spray drying, since it is a much less labor
intensive process compared to milling and roller compaction. Finally, drug loading (the ratio of drug
to drug + excipient, or the ratio of the drug mass to the actual pill that is produced) was tweaked
and very little impact was made on the economic fundamentals. The reason for this is that the sizing
of the spray dryers has a lot more to do with solubility; doubling the amount of excipient has a much
smaller impact than doubling the amount of solvent required, since the spray dryers need to match
the throughput of the slurry, and no matter what the solvent mass is going to be greater than the
excipient mass. Below is a graph showing the outcome of these tests:
5% annual TPC difference
1 ton
2x run time
reg run time
1/2 run time
75 CHF labor
100 CHF labor
125 CHF labor
25% load
37% load
50% load
10 ton
CHF 14,101.51
CHF 14,804.92
CHF 15,156.63
CHF 9,049.78
CHF 14,804.92
CHF 20,560.06
CHF 15,508.33
CHF 14,804.92
CHF 14,804.92
CHF
CHF
CHF
50 ton
120,794.16
156,065.95
156,065.95
CHF 99,264.07
CHF 156,065.95
CHF 212,867.83
CHF
CHF
CHF
156,065.95
156,065.95
156,065.95
100 ton
CHF 746,382.84
CHF 746,382.84
CHF 746,382.84
CHF 478,810.25
CHF 746,382.84
CHF 1,013,955.44
CHF 754,303.22
CHF 746,382.84
CHF 681,586.59
CHF
CHF
CHF
1,226,464.33
1,315,273.99
1,315,273.99
CHF 826,611.39
CHF 1,315,273.99
CHF 1,803,936.60
CHF
CHF
CHF
1,350,382.70
1,315,273.99
1,226,464.33
Figure 31: Sensitivity analysis
Although the labor costs do impact the economic benefit substantially, they have very little impact
on the break-even point for solubility. Variance of solubility with labor costs and the impact on
savings are shown below for 1 ton/day drug demand (and the results are similar for all drug
demands); they are "jumpy" because the spray drying equipment purchasing is discrete, not
continuous:
__ II _ 11.111..1_.1 . _1..1._._ I.l^i._.l. I._..I..- 1 . _ .1..1_1.. 1._.-.1_.. ~.~......
solubility
CHF 40,000.00
CHF 35,000.00
CHF 30,000.00
CHF 25,000.00
CHF 20,000.00
CHF 15,000.00
CHF 10,000.00
CHF 5,000.00
CHF Ol10
2.00% 4.00% 6.00% 8.00% 10.00% 12.00%
Figure 32: Impact on labor rates on break-even solubility
3.5 Conclusion of Economic Investigation
This model, given the proper input data, can accurately reflect the advantages and disadvantages of
spray drying when compared with milling and roller compaction. It was determined that drug
solubility is a crucial value, and that my experiments were all done at too high a solvent mass from
an economic standpoint. What this means is that for drug X specifically we need to find a solvent
that it is acceptably soluble in and check product stability. The more soluble the drug is in the
solvent, the higher the economic benefit of spray drying. For a 100 ton/year drug product, there is a
potential to save as much as three million dollars a year by implementing spray drying.
4 Discussion
4.1 Three Lens Analysis
In the following analysis, it is incredibly important to remember two things:
0.00%
__ ~_1_1_1__1___1_111____--~-------.~-^-l-i _ 111_^~___1_1^1___1__1_ 1_11___ _1_ ~ ~1
- 75 CHF/hr
oa-*100 CHF/hr
-* 125 CHF/hr
1. Spray drying will only be effective for a subset of Novartis' drugs
2. Continuous manufacturing will only be effective for a subset of Novartis' drugs
The overlap of these two is questionable. In some cases, spray drying may be a slam-dunk but
continuous manufacturing will prove impossible. In other cases, cheaper methods may exist to
accomplish the same tasks as spray drying, and continuous manufacturing will be the most
economically viable mode to production. Despite this, where both spray drying and continuous
manufacturing are applicable are where we see a lot of value created, and the most strategic and
political changes. It is difficult to ascertain the cultural impact of these various scenarios, since they
are confined to specific drugs and not the entire organization. However, the push for continuous
manufacturing wherever possible will have definite cultural consequence.
Those two caveats may mean that the best way to achieve value is to split departments even further.
Essentially, within Technical Research and Development (TRD) and Technical Operations
(TechOps) dedicate personnel to continuous manufacturing. Within TRD, have some individuals
determine feasibility of spray drying under the continuous manufacturing umbrella, and with
TechOps have operations personnel dedicated to continuous processing that can train other
operators in batch processing how to operate spray dryers.
This sort of division may lead to competition among continuous and batch TRD and TechOps, but
it would result in an effective distribution of control.
Strategic Lens
In a vacuum, the implementation of a new manufacturing technique rarely has implications for the
strategic design of an organization. The hierarchies, cross-divisional ties, and knowledge sharing
should in general stay the same. However, spray drying is unique in that it serves to bridge two
wholly dissimilar processes - Chemical Operations (ChemOps) and Pharmaceutical Operations
(PharmOps). In one case, you have individuals focused on generating a Drug Substance (DS), and in
another you have individuals focused on processing the DS in such a way that you end up with the
desired Drug Product (DP). Any implementation of spray drying would require a huge shift in the
ideas of where one division takes over and another relinquishes control.
In effect, spray drying would cause the boundary between ChemOps and Pharmops to be blurred.
The question is, does this only impact the production, or are other parties affected? In my time at
Novartis I worked with individuals from TRD and TechOps. When I gathered my data for building
the economic model I worked with scientists from Chemical Development (CHAD) and
Pharmaceutical Development (PHAD), operations personnel from ChemOps and PharmOps, and
financial analysts from CHAD, PHAD, ChemOps, and PharmOps. In short, the entire organization
of Novartis after Drug Discovery is separated along the lines of chemical and pharmaceutical
objectives, including normally centralized personnel like financial analysts. As a result, implementing
spray drying would require at the very least a redrawing of the traditional lines of chemical and
pharmaceutical development and operations in oral dosage forms, since those are the only forms
that spray drying have been shown to be useful for.
As it stands now, control is passed from chemical personnel to pharmaceutical personnel when the
DS is formed. The DS, in preparation for an oral dosage form, is a finely ground API that can easily
be combined with excipient for final pressing into a tablet form of the DP. With spray drying, where
would we draw this new line of control? A natural solution is to shorten the end game in ChemOps
and perform spray drying under the PharmOps umbrella. Essentially, once the Active
Pharmaceutical Ingredient (API) has been synthesized and separated from other compounds in
ChemOps, ship the solid to PharmOps and allow them to dissolve the API in a solvent, add
excipients, and commence spray drying. Although perhaps harder to identify, implications on TRD
would be substantial as well, particularly in PHAD. Spray drying has the potential to replace many
pharmaceutical techniques that have not been fully explored, like varying modes of granulation and
compaction, all of which have their dedicated scientists and engineers. Furthermore, spray drying
knowledge is only held by a small subset of scientists in PHAD, and thus their group would have to
expand.
While this solution may be worthwhile for implementing spray drying alone, it does nothing to
address the fact that spray drying is a step on the road to continuous manufacturing. My analysis was
done on spray drying alone to show that it could be effective on its own, but in the context of
continuous manufacturing it is easy to see that the strategic implications are even more drastic. All
of the divisions between ChemOps and PharmOps would be dissolved, since manufacturing would
be taking place in one single facility. TRD would have to be much more integrated, since it would be
possible to extract much more value if processes upstream were to increase the yield and decrease
the costs of processes downstream. Optimizing the system as a whole would be a possible and real
goal, and thus the design of TRD would have to stress this synergy.
Cultural Lens
As discussed earlier, the implications of spray drying being implemented on one specific drug may
not have cultural consequences, but just the mere fact that Novartis is considering continuous
manufacturing does change the norms of the organization. Continuous manufacturing is a paradigm
shift in drug manufacturing for Novartis and as a result the people who are involved are enthusiastic.
However, this enthusiasm may not spill over to people who have dedicated their careers to
conventional manufacturing. The symbolic meaning of this project is different for different people -
in some cases, it is another example of why Novartis is doomed to fail, and in other cases, it is step
toward the future that could result in huge gains for Novartis in the battle for market share.
Political Lens
My project relates directly to the politics of this organization. If spray drying is implemented on one
or more drugs, different skills will start to be valued more and others may no longer matter. Experts
in wet granulation, roller compaction, and milling may begin to feel marginalized since their
techniques are no longer the most desirable from an economic standpoint, and they may feel like the
organization is blazing a trail and leaving them behind. Individuals who are not part of the
continuous manufacturing initiative may feel left out as well.
Power is distributed quite widely in this project. TechOps is managing the continuous
manufacturing initiative, but has to rely on PHAD and CHAD to actually execute. Within PHAD
there are experts in conventional pharmaceutical manufacturing as well as spray drying, so the
experts in spray drying have more impact. The fact that TechOps is pushing this but TRD has veto
power with respect to what compounds to consider can result in communication problems and slow
progress. At this stage, simply identifying a compound to try this technique on is difficult because so
many individuals have so many responsibilities that lie outside of the spray drying / continuous
manufacturing umbrella.
Once spray drying is implemented, there will be a small shift in power from ChemOps to
PharmOps. At the same time though, since more value added activities will shift to PharmOps,
ChemOps plants may look better (have lower costs) and PharmOps plants may look worse.
Whoever is designing incentives for the managers of these disparate facilities will need to take this
into account, and any increase in ChemOps profitability should be scrutinized carefully. A very real
danger is the project proposal for spray drying to pass, design and development completed, and then
PharmOps plants are perceived as slacking because they are learning how to accommodate this new
type of input and implement this new process. Too often, a change is made with good intentions but
then stopped because people not involved with the change see the effects and do not know how the
change can have domino effects.
4.2 Summary
My project grew out of the Novartis - MIT Continuous Manufacturing Center, as a way to strength
the case for continuous manufacturing. What I have shown is that spray drying can in some cases
stand up on its own, as a new manufacturing technique implemented in currently existing PharmOps
facilities. The degree of economic benefit is related most directly to the solubility of the API in a
common solvent that can be used for spray drying, and can be on the order of millions of dollars per
year per drug. In addition, what I have shown through my three lens analysis is that actually putting
spray drying in action could have definite consequences for the strategic organization and a little less
impact politically. Since my research and analysis were done with spray drying of pharmaceuticals in
a nascent stage, it would be premature to demand immediate implementation of spray drying.
Furthermore, the compound I worked with is not a good candidate for spray drying. However, I
have laid a path for future experimentation and analysis. The next compound tested should have
these characteristics:
* Low hazard (less than Category 3) to allow for quicker experimentation
* High solubility (>3%) in a common solvent
* Suitable for oral dosage form
Attributes that would increase the economic viability of spray drying this compound:
* Simple end game (crystallization serves to simply separate API from solvent, not from other
potentially harmful compunds)
* Complex PharmOps processing
X-ray diffraction (XRD) will provide insight on the materials structure of spray dried drug &
excipient. Stress testing should be completed for at least four weeks using sodium chloride at 40
degrees Celsius. Economic analysis can be carried out in a similar way as the model I have presented
in this paper.
Once spray drying experiments are carried out with this new drug, it will be necessary to finally test
if the product can be pressed into a tablet. If this step is reached, it may be possible to pilot spray
drying within a PharmOps facility in conjunction with a corresponding ChemOps facility. Once the
economic benefit identified, analysis should be done to measure the gap between projected benefit
and actual benefit. If the actual benefit is proven to be substantial, spray drying should be spread
throughout facilities producing the drug.
In the context of continuous manufacturing, where an entire plant is being produced from scratch,
spray drying will be part of the process from the ground up at a Greenfield site.
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APPENDIX I
Differential Scaling Calorimetry (DSC) results:
DSC measurements were taken to further characterize the samples.
TO [C Melting oint [C1 Enthalpy of melting [Jig]
Avicell 20-80 134.92, 183.75 204.76 26.4
Avicell 50-50 139.36 208.34 16.21
Avicell 80-20 142.07 -
PVP 20-80 136.42 -
PVP 50-50 158.09 - -
PVP 80-20 117.62 - -
Lactose 50-50 118.43 183.2 49.9
Aerosil 50-50 140.64 - ... . ..-
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